JAMES M FRATES
CIK 1235598 · Chief Financial Officer · last filed 2026-03-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$20.45M
Companies
3
Total Filings
214
Lifetime Open-Market Net
-$42.52M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AMLX | Chief Financial Officer | 361,628 | $24.19 | $8.75M | -$3.22M | 23 | 2026-03-09 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | 1,810 | $8.68 | $15.7K | -$4.48M | 21 | 2025-07-31 |
| ALKS | SVP, Alks Inc; CFO ALKS | 241,828 | $48.37 | $11.70M | -$34.81M | 166 | 2020-05-14 |
Recent Filings · Page 4 of 22
214 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-01-04 | AMLX | Exer (M) | +5,000 | $34.4K | EDGAR |
| 2022-06-17 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-28 | AMLX | Grant (A) | — | $0 | EDGAR |
| 2022-01-10 | AMLX | Grant (A) | +31,667 | $0 | EDGAR |
| 2021-06-17 | Sage Therapeutics, Inc. (SAGE) Delisted | Buy (P) | +1,810 | $99.7K | EDGAR |
| 2021-06-11 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-11 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-14 | ALKS | Exer (M) | +21,983 | $258.1K | EDGAR |
| 2020-03-03 | ALKS | Mixed | +3,177 | -$27.6K | EDGAR |
| 2020-02-24 | ALKS | Mixed | +4,113 | -$34.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.